Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.
Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.
Gamble says that at first, everyone was very excited when this rule came out. However, he suggested that cuts to drug payments have benefitted hospitals in the 340B program.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More